929302-00-1

Basic information

• Product Name: 4-Cyano-4-(toluene-4-sulfonyloxyMethyl)-piperidine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-Cyano-4-(toluene-4-sulfonyloxyMethyl)-piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 929302-00-1
• Molecular Formula: C₁₉H₂₆N₂O₅S
• Molecular Weight: 394.48514
• EINECS: -0
• Mol File: 929302-00-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Cyano-4-(toluene-4-sulfonyloxyMethyl)-piperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Cyano-4-(toluene-4-sulfonyloxyMethyl)-piperidine-1-carboxylic acid tert-butyl ester(929302-00-1)
• EPA Substance Registry System: 4-Cyano-4-(toluene-4-sulfonyloxyMethyl)-piperidine-1-carboxylic acid tert-butyl ester(929302-00-1)

Safety Data

• Hazardous Substances Data: 929302-00-1(Hazardous Substances Data)

Upstream product

• 498-94-2 isonipecotic acid 
• 39546-32-2 4-carboxamidopiperidine 
• 2971-79-1 isonipecotic acid methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1016258-66-4 1-(tert-butyl) 4-ethyl 4-cyanopiperidine-1,4-dicarboxylate 
• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 
• 4395-98-6 4-cyanopiperidine 
• 614730-96-0 tert-butyl 4-cyano-4-(hydroxymethyl) piperidine-1-carboxylate 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1345728-66-6 2-benzyl 7-(tert-butyl) 2,7-diazaspiro[3.5]nonane-2,7-dicarboxylate 
• 1023301-84-9 tert-butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate hydrochloride 

Relevant articles and documents

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF

The invention provides compounds having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated with the mediation of sodium channels, and compositions containing such compounds and methods for using such compounds and compositions.

SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula I wherein R1, R2, R3, R4, R5, Ra, Rb, Rc, Rd, Re, n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF

The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors

The triaryl bis-sulfone 1 was modified by converting the aryl A-ring to a piperidine ring. The piperidine ring was further elaborated to a spirocyclopropyl piperidine moiety. The effect on CB2 binding potency, rat calcium channel affinity, and CYP 2C9 inh

NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES

The invention provides compounds of general formula (I) wherein A, B, p, w, x, y, and z are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.